Nutritional and endocrine factors in reproductive organ cancers: opportunities for primary prevention

Significance of Leydig Cell Neoplasia in Rats Fed Lactitol or Lactose

Lactitol is a disaccharide sugar alcohol (polyol) which is derived from lactose by catalytic hydrogenation and which may be used as a noncariogenic, reduced calorie sugar substitute in different foods. In the context of the safety evaluation of lactitol, a chronic carcinogenicity/toxicity study was conducted in a Wistar-derived strain of rats. In addition to effects that occur commonly in rats fed high doses of polyols, an increased incidence of Leydig cell tumors was observed in rats fed a diet with 10% lactitol for their lifetime. A comparison group receiving a diet with 20% lactose exhibited the same effect. At the 5% dose level of lactitol, no testicular changes were seen. Although lactitol is not genotoxic in standard in vitro tests and was also not associated with tumor formation in female rats and mice of either sex, it was necessary to assess the relevance of the testicular neoplastic growth for human safety. A comparative evaluation of the spontaneous and chemically induced formation of Leydig cell tumors in rats and humans demonstrates that the spontaneous occurrence is extremely low in humans but rather high in rats. Chemical agents or experimental conditions that in rats are associated with interstitial cell hyperplasia or neoplasia have not been associated with similar effects in humans. This is also true for lactose which, in Western countries, is consumed regularly and in substantial amounts with dairy products. Since lactitol is essentially not hydrolyzed in the small intestine, it gains access to the metabolism only after fermentation by the intestinal flora. It is therefore reasonable to assume that the testicular effects of lactitol and lactose were mediated by changes in the digestive tract such as by the known increase of calcium absorption which occurs in lactitol- and lactose-fed rats but not in humans or by effects of these compounds on the enterohepatic cycling of steroid hormones. Although these mechanisms are not yet elucidated, the available data on Leydig cell tumors indicate that the effects seen in male rats are not relevant to humans. The major lines of evidence supporting the human safety of lactitol and lactose are: (1) the lack of genotoxicity of lactitol, (2) the rat specificity of the testicular effects of lactose and lactitol, (3) the long history of safe consumption of lactose in humans, (4) the insensitivity of the human Leydig cells to agents and conditions that are known to cause neoplastic growth of Leydig cells in rats, (5) the generally very low spontaneous incidence of Leydig cell tumors in the human population, and (6) the absence of any epidemiological evidence establishing a link between nutritional factors and the occurrence of Leydig cell tumors in humans.

Prostate cancer screening: promise and peril--a review

This review summarizes the current status of and recommendations for prostate cancer screening with prostate-specific antigen in light of recent reductions in prostate cancer incidence and mortality. It describes how the uncertain effectiveness of aggressive treatment for prostate cancer and a reservoir of unsuspected indolent cancers make prostate cancer fit poorly into conventional screening models. The large proportion of men with unsuspected prostate cancers that may not cause morbidity or mortality and are unlikely to benefit from aggressive treatment decrease the effectiveness of a screening program. In addition, indolent, unsuspected prostate cancers in the screening population accentuate the detrimental effects of length bias on studies evaluating the effectiveness of prostate cancer screening. Screening tests for prostate cancer will continue to improve, but chemoprevention or nutritional prevention with vitamins and micronutrients such as tocopherols or selenium may prove to be effective methods of reducing prostate cancer incidence and should be aggressively investigated.

Progetto ATENA, a study on the etiology of major chronic diseases in women: design, rationale and objectives

In spite of their important impact on populations, a number of diseases--all types of cancer and coronary heart disease in women--are "rare" events for statistical analysis and often analyzed in designs affected by selection and information biases, such as case-control studies. Large cohort studies based on the storage of biological specimens appear to be the most suitable solution for identifying risks for those diseases. Progetto ATENA, a study on the etiology of major chronic diseases in women is based on this design. Ten thousand women, aged 30-69 years, living in the area of the city of Naples, free of cancer and cardiovascular disease, are being recruited over a four-year period. Ten per cent of the cohort is being randomly selected from the electoral roles, the rest will be volunteers. Information on dietary habits, reproductive history, familiarity for chronic disease, active smoking habits and passive smoking exposure, physical activity, and socio-demographic data are being collected. Clinical data such as blood pressure, anthropometry, and electrocardiogram are also taken. All the participants provide biological samples of blood (fasting drawing) and urine (timed morning spot). The biological samples are processed in order to explore the main areas under study (nutritional markers, metabolism, endocrinology, genetics, environmental exposure markers, thrombogenesis). The samples are stored in liquid nitrogen (-196 degrees C) as soon as the blood and urine processing have been finished. An appropriate follow-up information system on the health status of the participants is being set up to estimate incidence and mortality rates.

Patterns and risks of cancer in farmers in Alberta

Data on occupations and life styles of patients with cancer have been collected since 1983. To investigate cancer patterns and risks in farmers in Alberta, all farmers were abstracted and compared with nonfarmers in the data base, using case-control analysis. Controls were patients with cancer at any site except the index site. Significantly elevated odds ratio (OR), adjusted for age and smoking, were found among the farmers for cancers of the lip (OR = 3.22, 95% confidence interval [CI] = 2.14 to 4.84) and prostate (OR = 1.31, 95% CI = 1.11 to 1.55). Crude risk for lung cancer was significantly lower in farmers, but statistical significance disappeared when risk was adjusted for smoking (OR = 0.81, 95% CI = 0.65 to 1.02). Farmers were at considerably lower risk of malignant melanoma of the skin, compared with nonfarmers (OR = 0.57, 95% CI = 0.36 to 0.91).

Approaches to breast cancer prevention

It may be possible to delay the step-by-step progression towards frank invasive cancer by avoiding one or more of the well-known clinical risk factors. In addition current clinical trials in the USA and Europe are assessing whether the use of tamoxifen, vitamin analogues or a low-fat diet can delay the appearance of overt disease in women known to be at high risk, but it will be several years before such trials can be evaluated. For women seeking advice on prevention, non-toxic supplements to the diet such as beta-carotene, vitamin A analogues or selenium compounds, and the avoidance of alcohol and obesity, are examples of practical advice which can do no harm yet may help to protect against breast cancer development. In the case of the very anxious first degree relative of a breast cancer patient, the current choice lies essentially between regular monitoring, mastectomy with reconstruction, early termination of ovarian activity and anti-oestrogen therapy. Currently, considerable research is being directed towards identifying oncogenes and growth factors which are involved in the growth of breast cancer. In the meantime, more research needs to be devoted to the effect of various progestagens in counteracting oestrogen support of breast cancer growth, and to biological observations on different formulations and doses of combined oestrogen/progestagen preparations which may reduce breast cancer risk both in pre- and postmenopausal women.